ClinicaliQ Trial Snapshot
- A Phase 1 Study of CTIM-76 in Patients With Recurring Ovarian Cancer and Other Advanced Solid Tumors — Recruiting • Phase I • Oncology • NCT06515613.
- What is being tested: CTIM-76, a CLDN6-directed T cell-engaging bispecific antibody, is being evaluated in a Phase 1a/1b dose escalation and expansion study to assess safety and efficacy in patients with platinum-refractory/resistant ovarian cancer and other advanced CLDN6-positive solid tumours.
- Patient eligibility overview: The trial includes patients with platinum-refractory/resistant ovarian cancer (PRROC) and other advanced solid tumours that express CLDN6; this addresses a treatment-resistant patient population with limited therapeutic options and poor prognosis.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
This is a Phase 1a/1b, open-label, dose escalation and expansion study to evaluate the safety and efficacy of CTIM-76 (study drug), a CLDN6-directed T cell-engaging bispecific antibody , in participants with platinum-refractory/resistant ovarian cancer (PRROC) and other advanced CLDN6-positive solid tumors (i.e., testicular and endometrial).
Eligibility Snapshot
- : * Participants with CLDN6 positive platinum resistant/refractory ovarian, advanced testicular or advanced endometrial cancer. * Participants with measurable disease per RECIST 1.1. * ECOG 0, 1, or 2 and life expectancy of ≥ 12 weeks. * Participants with adequate organ function.
Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.